Ellen Donnelly

Chief Executive Officer at ABLIVA AB

50 year

Health Technology

Finance

Consumer Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
Eskil Elmér	M	54	ABLIVA AB	24 years
Viktor Drvota	M	59	MODUS THERAPEUTICS HOLDING AB Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	8 years
John Öhd	M	53	MODUS THERAPEUTICS HOLDING AB Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	6 years
Catharina Jz Johansson	F	57	ABLIVA AB	11 years
Johan Sandin	M	54	ALZECURE PHARMA AB	8 years
David Laskow-Pooley	M	69	ABLIVA AB	8 years
Torsten Rüdiger Goesch	M	65	MODUS THERAPEUTICS HOLDING AB Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	10 years
David Bejker	M	49	ABLIVA AB	7 years
Ragnar Linder	M	71	ALZECURE PHARMA AB	7 years
Eva Lilienberg	F	68	ALZECURE PHARMA AB	3 years
Mikael Widell	M	-	ALZECURE PHARMA AB	-
Denise Goode	F	66	ABLIVA AB	6 years
Jan Birger Fredrik Toernell	M	64	ABLIVA AB	7 years
Martin Jönsson	M	56	ALZECURE PHARMA AB	4 years
Bror Thomas Pollare	M	71	ALZECURE PHARMA AB	7 years
Johan Dighed	M	51	Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	-
Janet Hoogstraate	M	57	ALZECURE PHARMA AB	1 years
Eleonor Asander Frostner	F	43	ABLIVA AB	13 years
Magnus Hansson	M	48	ABLIVA AB	16 years
Birgitta Lundvik	F	57	ALZECURE PHARMA AB	7 years
Märta Segerdahl	M	68	ALZECURE PHARMA AB	3 years
Erik Aksel Bork	M	42	Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	3 years
Joakim Notö	M	-	Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	-
Roger Franklin	M	45	ABLIVA AB	4 years
Claes Lindblad	M	57	MODUS THERAPEUTICS HOLDING AB	3 years
Dag Nesse	M	-	ABLIVA AB	1 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Gunnar Magnus Modee Persson	M	64	ABLIVA AB	2 years
Erik Kinnman	M	66	ABLIVA AB	5 years
An van Es-Johansson	M	64	ALZECURE PHARMA AB	3 years
Matilda Hugerth	F	49	ABLIVA AB	5 years
Mats Blom	M	59	Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	2 years
Pirkko Sulila Tamsen	M	65	ALZECURE PHARMA AB	-
Christina Elisabeth Herder	M	63	Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	3 years
Lena Jendeberg	M	60	Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	-

Statistics

Country	Connections	% of total
Sweden	34	100.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections